Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNB4 | O00305 | 5/20 | 0.55 |
| ▸ | CACNA1A | O00555 | 5/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 5/20 | 0.55 |
| ▸ | CACNG3 | O60359 | 5/20 | 0.55 |
| ▸ | CACNA1F | O60840 | 5/20 | 0.55 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.55 |
| ▸ | CACNB3 | P54284 | 5/20 | 0.55 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.55 |
| ▸ | CACNG7 | P62955 | 5/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.55 |
| ▸ | CACNA1D | Q01668 | 5/20 | 0.55 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.55 |
| ▸ | CACNG1 | Q06432 | 5/20 | 0.55 |
| ▸ | CACNB2 | Q08289 | 5/20 | 0.55 |
| ▸ | CACNA1S | Q13698 | 5/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 5/20 | 0.55 |
| ▸ | CACNA1E | Q15878 | 5/20 | 0.55 |
| ▸ | CACNA2D4 | Q7Z3S7 | 5/20 | 0.55 |
| ▸ | CACNA2D3 | Q8IZS8 | 5/20 | 0.55 |
| ▸ | CACNG8 | Q8WXS5 | 5/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4399845 | 0.85 | CACNB4 (0.54) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL13594352 | 0.80 | F2R (0.43) | F2RENPP2CYSLTR2CYSLTR1 | |
| SCHEMBL4399843 | 0.73 | CACNB4 (0.50) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL4402395 | 0.70 | HASPIN (0.47) | F2RENPP2CYSLTR2CYSLTR1 | |
| SCHEMBL13594356 | 0.68 | F2R (0.42) | F2RENPP2CYSLTR2CYSLTR1 | |
| SCHEMBL23011425 | 0.68 | CIT (0.55) | — | |
| SCHEMBL4405459 | 0.67 | ENPP2 (0.40) | F2RENPP2MCHR1 | |
| SCHEMBL2567446 | 0.65 | AAK1 (0.49) | — | |
| SCHEMBL3017458 | 0.65 | CTSS (0.59) | — | |
| SCHEMBL5255070 | 0.65 | CACNB4 (0.47) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629319-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-12-08 | — | — | US | disclosed |
| US-7618945-B2 | Heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-11-17 | — | — | US | disclosed |
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-01-12 | — | — | US | disclosed |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | JANSSEN PHARMACEUTICA, NV (BE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009396-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | CACNB4 3941/4885CACNA1A 4608/4885CACNA1G 3266/4885 |
| US-20040138141-A1 | Novel heteroaryl peptidomimetics as thrombin receptor antagonists | PTAFR, F2R, F2RL1 | CACNB4 3941/4885CACNA1A 4608/4885CACNA1G 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.